NeuroVive Pharmaceutical AB Vállalati érték
Mi az NeuroVive Pharmaceutical AB Vállalati érték?
A Vállalati érték az NeuroVive Pharmaceutical AB - $10.23M
Mi a Vállalati érték meghatározása?
A vállalati érték a vállalat teljes piaci értékének mértéke. A piaci kapitalizáció az adósság, a kisebbségi részesedés és a preferált részvények összege, a pénzeszközök és pénzeszköz-egyenértékek összege mínusz.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Vállalati érték a Health Care szektor a OTC-on cégekben a NeuroVive Pharmaceutical AB -hoz képest
Mit csinál NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
vállalati érték -hoz hasonló cégek NeuroVive Pharmaceutical AB
- Fuel Tech Inc nak Vállalati érték $10.20M van
- Clifton Mining Co nak Vállalati érték $10.21M van
- Mosaic ImmunoEngineering nak Vállalati érték $10.22M van
- Pembridge Resources plc nak Vállalati érték $10.23M van
- Sky Metals nak Vállalati érték $10.23M van
- Aurora Minerals nak Vállalati érték $10.23M van
- NeuroVive Pharmaceutical AB nak Vállalati érték $10.23M van
- I Synergy nak Vállalati érték $10.24M van
- Valhalla Metals nak Vállalati érték $10.24M van
- Ocean Grown Abalone nak Vállalati érték $10.24M van
- Peeks Social nak Vállalati érték $10.24M van
- Diagnos nak Vállalati érték $10.25M van
- Inventis nak Vállalati érték $10.25M van